000 01312 a2200325 4500
005 20250515230041.0
264 0 _c20100727
008 201007s 0 0 eng d
022 _a1535-5667
024 7 _a10.2967/jnumed.109.073445
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSlifstein, Mark
245 0 0 _aWhen reversible ligands do not reverse, and other modelers' dilemmas.
_h[electronic resource]
260 _bJournal of nuclear medicine : official publication, Society of Nuclear Medicine
_cJul 2010
300 _a1005-8 p.
_bdigital
500 _aPublication Type: Journal Article; Comment
650 0 4 _aBenzazepines
_xchemistry
650 0 4 _aLigands
650 0 4 _aModels, Structural
650 0 4 _aNervous System
_xdiagnostic imaging
650 0 4 _aNiacinamide
_xanalogs & derivatives
650 0 4 _aPositron-Emission Tomography
_xtrends
650 0 4 _aRadiopharmaceuticals
_xchemistry
650 0 4 _aReceptors, Drug
_xmetabolism
650 0 4 _aReceptors, Histamine H3
650 0 4 _aReference Standards
650 0 4 _aTomography, Emission-Computed, Single-Photon
773 0 _tJournal of nuclear medicine : official publication, Society of Nuclear Medicine
_gvol. 51
_gno. 7
_gp. 1005-8
856 4 0 _uhttps://doi.org/10.2967/jnumed.109.073445
_zAvailable from publisher's website
999 _c19903839
_d19903839